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During the spread of the COVID-19 pandemic, many health-related industries were alarmed and 
pressured to innovate solutional vaccines to reduce the effect of the COVID-19 pandemic. Extra effort 
and lab activities had taken place in several jurisdictions to respond to the increased demand for the 
COVID-19 vaccine. With these attempts, various vaccines were created and entered the market. All 
countries designed their own COVID-19 programme in the route to combat the viruses. These 
countries showed their willingness to invest to secure access to vaccines. In parallel to this 
development, the vaccination program is bombarded with several issues such as safety assurance, equal 
access to the vaccine, and protests by the anti-vaccine group. The inability to address these issues will 
jeopardise the success of building herd immunity which is the core in eradicating COVID-19 cases. 
Thus, this study explored and analysed the issues and challenges to have an effective vaccination 
program in a battle against the spread of the COVID-19 virus. It is a comparative study between 
Malaysia and Australia that includes safety measures, anti-vaccine groups and access to vaccines. This 
study adopts a qualitative method utilising the doctrinal study on the legal framework that describes the 
scope and limitation of power accorded to the Drug Control Authority of the selected jurisdictions. The 
research activities also include semi-structured interviews with relevant authorities using online 
interviews. The data are analysed using content and thematic analysis. Findings to this study may assist 
in identifying the loopholes within the administrative control on the vaccination program adopted by 
Malaysia. 
 






COVID-19 vaccine has been regarded as one of the well-received options to manage the global 
pandemic. Tainted with negative perceptions of its safety and efficacy, especially during its early 
phase, it is crucial to alleviate the public concern and vaccine hesitancy group. In their articles, 
Borriello et al. (2021) disclosed that concerns regarding vaccine safety are indeed a significant 
component in the surge of vaccine hesitancy. It is especially true in the present COVID-19 pandemic, 
where vaccines are being developed at a rapid pace. The public concerns on safety affirmations of 
vaccine products (Bernama, 2021; Wan Abhar, 2021) were instigated by the widely spread information 
on the adverse effect of vaccination. The queries regarding the safety of vaccines are related to 
speculation on the insufficient period of efficacy testing (Kaur et al., 2021) the unestablished report on 
the adverse reaction towards the newly invented vaccine, the active components in the vaccine, and the 
halal status of the vaccine (Khoo et al., 2020). The arrival and distribution of safe, effective COVID-19 
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vaccines are the significant development in the coronavirus pandemic. As more people are vaccinated, 
families and communities will be able to gradually return to a more normal routine (Lisa & David 
Kelen, 2021). Responding to the demand for safety assurance of the vaccine products, pharmaceutical 
control authorities of all countries experienced the increased burden in finding and innovating 
solutional vaccines to curb the spread of the COVID-19 virus and assure the safety of the people. 
Developing pharmaceuticals usually requires a more extended testing period to ensure the safety, 
efficacy, and quality aspects of the newly invented drug and the vaccine. This study investigates the 
power and role of the Pharmaceutical Control Authority of Malaysia and Australia to consolidate the 
best practice adopted by these jurisdictions. The findings assist in formulating recommendations for 
appropriate legal measures to control the safety and efficacy of vaccines during the crisis. The study 
adopts a qualitative research methodology utilising doctrinal study and semi-structured interviews. The 
data acquired through doctrinal research and semi-structured interview are integrated and analysed 
using content and thematic analysis.  
 
 
Literature Review  
 
Immunisation has long been introduced to address the issue of fatal infectious diseases caused by 
pandemics or epidemics (Joslyn Panting et al., 2018; Wong & Lee, 2021). History recorded that at 
every spread of a pandemic, the healthcare practitioners, researchers, and policymakers around the 
globe were thrown a challenge to deliver adequate prevention and treatment modalities to combat the 
pandemic (Kaur et al., 2021; Kashte et al., 2021; Deplanque & Launay, 2021). Much research was 
carried out on this area covering related issues like the development of vaccines (Mukherjee, 2020), the 
emergence of the vaccine-hesitant group, the impact of non-vaccinated children on the future 
population, the adverse impact of vaccination (Mukherjee, 2020), and innovation of new vaccine (Lisa 
& David Kelen, 2021). Studies in other countries have documented various factors affecting parents’ 
decision to vaccinate their children Khoo et al. (2020). 
  
The writings (Wan Taib et al., 2017; Joslyn Panting et al., 2018; Silva et al., 2021) on the emergence of 
hesitant vaccine groups agree that the attitude and behaviour of the followers of the hesitant group do 
have a future impact on the society. The tendency of epidemic or pandemic revival is one of the future 
impacts (Joslyn Panting et al., 2018). The root of the rejection of vaccine uptake provides material 
information for the government planning to achieve herd immunity (Silva et al., 2021) and eradicate 
the pandemic. Concerning this, a study by Rumetta et al. (2020) highlighted that vaccine-related 
diseases are increasing in developing countries. Both Rumetta et al. (2020) and Joslyn Panting et al., 
(2018) used an attitude-based model to identify the causes of the targeted group hesitancy act. Under 
these studies, doubting the halal status of the vaccine was not one of the factors identified. 
  
Although these articles contributed to explaining Malaysian acceptance behaviour towards vaccination, 
it has not addressed the importance of determining the vaccine's halal status. However, the review 
made by Khoo et al., (2020) consolidated the unique considerations for manufacturing and the 
regulation of new vaccines in Muslim-populated countries such as Malaysia. On the area of vaccine's 
safety and efficacy, to date, there is no comprehensive review of safety data reported from the vaccine 
trials, which forms a piece of critical information for the policymaker to improve uptake of COVID-19 
vaccines and mitigate the risk aversion perceived due to the COVID-19 vaccine side effects (Kaur et 
al., 2021; Kashte et al., 2021; Deplanque & Launay, 2021). In a report, (The Secretariat of the Special 
Committee for Ensuring Access to Covid-19 Supply (JKJAV), 2021) it was said that in negotiations for 
the purchase of the COVID-19 vaccine, the Malaysian government has included value-added elements 
to enable Malaysia to develop our vaccine development capacity in the country (Ramli et al., 2020). 
Although this study had researched the procedures to create a permissible vaccine, an in-depth 
discussion on the role of the Drug Control Authority was absent. 
  
Another area explored by previous authors is the right to vaccine access. Sharun & Dhama, (2021) 
discussed the importance of equal access to the COVID-19 vaccine, responding to the latest COVID-
19 vaccine products that were excessively conquered by the developed countries to the detriment of 
insufficient vaccines for developing countries. On a similar issue, Kuok & Wong (2021) wrote on the 





vaccine administration and immunisation plans that are unveiled every day and how the authorities 
have also been quick to issue warnings on "queue jumping". Based on the precedent literature, it can be 
summarised that although much research has been carried out on the COVID-19 vaccine, an in-depth 
comparative discussion on the role of Drug Control Authorities of different world countries has not 





This research employed a qualitative approach. The methods involved the collection, analysis, and 
integration of various sources of qualitative data. The researchers used the literature review to generate 
a specific set of theories and later integrated and corroborated the generated ideas through semi-
structured interviews. 
  
Phase 1 Literature Review 
 
i. Critically reviewed all literature on the concept and issues relating to vaccines together with 
their monitoring/control measures from various sources including textbooks, journal articles, 
government reports, newspaper articles, and online sources. 
ii. Critically reviewed the role and power of the Drug Control Authorities in Australia and 
Malaysia to identify best practices that can be adopted to improve the existing role and power 
of the Malaysian Drug Control Authority in monitoring the COVID-19 vaccine. 
Phase 2 Data Collection 
 
i. A preliminary study was conducted to ensure the trustworthiness of the interview protocols 
and checklist. 
ii. The procedures of the qualitative data collection included examination of documents and semi-
structured interviews. The respondents were chosen based on a purposive sampling technique 
and based on their occupational roles. The semi-structured interviews involved the analysis of 
administrative records and reports. 
iii. For triangulation with the above-mentioned collected data, the primary data from semi-
structured interviews were combined with the preliminary findings gathered through analysis 
of documents. 
Phase 3 Data Analysis 
 
i. The grounded theory approach was adopted to analyse the qualitative data through thematic 
and content analyses, in which the interview transcripts were analysed. The process consisted 
of creating codes and categories, gleaning themes about the respondents' experiences. Also, 
such data were integrated with the experts’ opinions on the issues and the literature review. 
ii. The data analysis was conducted using qualitative software, ATLAS.ti version 9. 
iii. The results obtained from the primary and secondary data from the findings of the research 




The findings of this study uncover some similar challenges faced by the Malaysian and Australian 
governments in monitoring and controlling the safety and efficacy of COVID-19 vaccines. The 
findings are summarised in the following table that entails the key comparative points, including the 
safety assurance mechanism such as the clinical trial reliability, registration, and powers of the drug 
control authority. Other than monitoring the safety and efficacy aspects, the study also explores the 





pertinent issues attached to both jurisdictions' national COVID-19 vaccination program. Issues like the 
vaccine-hesitant group and adequate access to global vaccines are seen as threats to the government’s 
effort in combating the COVID-19 pandemic.  
 
Table 1: Comparative Analysis between Malaysia & Australia 
 
Comparative Points Malaysia Australia 
The Drug Control 
Authority 
National Pharmaceutical 
Regulatory Agency (NPRA) 
Therapeutic Goods 
Administration (TGA) 
TGA controls products that are 
listed as therapeutic goods 
including vaccines, at the federal 
level 
 
Usage approval/ Safety & 
Efficacy check 
Non-applicable for production of 
vaccines as Malaysia is a non-
producer of vaccines. 
The NPRA's evaluation is based on 






The provisional approval 
pathway (PAP). TGA will run 
checks on every batch of the 
vaccines. 
PAP is valid for an initial 
duration of two years, entitling 
the pharmaceutical companies to 
supply the vaccines to Australian 
populations legally. 
This period could be further 
extended for up to two extensions 
amounting to a maximum of six 
years upon the application of the 
pharmaceutical companies. 
  
Clinical trial Malaysia is a non-producer of the 
COVID-19 vaccine product. 
Overlapping method where the 
usual process is the phase-by-
phase process. 
 
Registration of vaccine COVID-19 vaccines in an ongoing 
Phase III clinical study or those 
authorised to use by any other 
DCA or WHO are eligible for 
conditional registration. 
The initial regulatory approval for 
the use of COVID-19 vaccines 
through the provisional 
determination and registration 
pathway 
 
Import of vaccine Only local distribution companies 
can submit a drug-based product 
registration application. 
Therefore, foreign companies with 
no local presence in Malaysia must 
use a Marketing Authorization 
Holder (MAH) as their local 
representative. 
MAH is responsible for the 
product application, as well as the 
quality, safety, and efficacy of the 
product (Regulation 7(1)(a), 
CDCR, 1984) 
  
Australia manufactures some of 
the vaccines. 
 
TGA provisionally registers the 
vaccine for imported vaccines 
before the vaccine is imported 
into Australia, subject to strict 
import requirements. 
 
The quality of every batch of 
vaccine is tested before it is 
supplied in Australia. 





Vaccine hesitancy Vaccination is voluntarily based. 
To curb the issue of anti-vaccine 
groups, there is a proposal for the 
implementation of mandatory 
immunization programs. 
Implementation of policies 
known as "No Jab, No Pay" and 
"No Jab, No Play" to eradicate 




Access to vaccination As a non-producer of vaccines, 
action has been taken to secure an 
agreement to ensure a sufficient 
supply of vaccines to all 
populations. 
 
Manufacturer of vaccine 
nevertheless to cater for all 
population has secured agreement 
for the supply of the vaccine. 
Legislation relating to 
COVID-19 Vaccination 
Poisons Act 1952 (Act 366) and its 
regulations 
 
Sale of Drugs Act 1952 (Act 368) 
and its regulations 
 
Drugs and Cosmetic Control 
Regulations 1984 
 
Infectious Disease Prevention and 
Control Act (Act 342) 
Therapeutic Goods Act of 1989 
Therapeutic Goods Regulations 
1990  
Gene Technology Act 2001 
 
 
The study showed that governments of both jurisdictions are committed to addressing issues of 
COVID-19. The curtailment of its spread became the main aim taking priority over other issues. When 
the Australian government has facilities and expertise in producing vaccines for local use, Malaysia, on 
the other hand, decided to secure the supply of vaccines from other countries. The decision was made 
based on several factors such as lack of expertise, absence of facilities to cater for an expedited 
innovation and production of vaccines, and insufficient human capital. Although Australia produces its 
vaccine, it has to enter into supply agreements with several international manufacturers to ensure 
access to vaccines for all of its population. In such a situation, the safety monitoring shifted from the 
clinical trial stage to checking and verifying the safety documents of the manufacturers. The existence 
of vaccine-hesitant groups is not uncommon in most jurisdictions. The most worrying is the increase of 
followers to these groups during the COVID-19 pandemic which may jeopardise the government's 
effort in upholding the rights to life of their people. Australia has previously introduced and 
implemented the “No Jab, No Pay” and “No Jab, No School” policies in response to the arrogant act of 
these groups. Although these policies were reported to have elevated the number of the pro-vaccine 
group, yet it is entangled with issues like rights of autonomy and privacy. The existing legislation of 
both jurisdictions comes into play during the increase of COVID-19 cases. It can be examined that 
there is no necessity for introducing new legislation shortly save for the introduction of mandatory 
vaccine law. There were executive actions that proposed introducing such a law, but currently, the 
legislative activity has not started in both countries. The following section discusses in-depth the issues 





Monitoring the Safety and Efficacy Aspects 
  
Before a vaccine can be commercialised, brought into the market, and eventually administered into 
human bodies, first and foremost, it has to be licensed by the Drug Control Authority (DCA) of any 
particular jurisdiction. The significance of the vaccine licensure is it assures that the vaccine is safe, 
efficient, and having the minimum qualification required to ward off any specific disease for which the 
vaccine has been developed. However, during the pandemic, some safety and efficacy measures need 
to be expedited to accelerate the production of the vaccine. The rapid spread of the deadly coronavirus 
disease 2019 worldwide following its emergence in Wuhan, China, in December 2019 has brought 





about unprecedented events. In keeping up with the spread and reducing morbidity and mortality, 
scientific progress needed to be accelerated to accommodate the development of vaccines at a speedier 
rate compared to the pre-COVID-19 era. Because of this, the World Health Organisation (WHO) has 
issued a master protocol publicly available from early March 2020 as guidance in harmonising 
COVID-19 clinical trials at the global arena (Davis et al., 2020). Coupled with the advancements in 
technology, as well as availability of funding and concrete collaboration between vaccine developers 
and the government (Department of Health, 2021a) the unbelievable speed of vaccine development in 
the COVID-19 era has been made possible due to the existence of studies and researches over previous 
comparable pandemics, such as the 2019 H1N1 influenza pandemic, the 2012 Middle East respiratory 
syndrome (MERS) and the 2003 severe acute respiratory syndrome (SARS) (Davis et al., 2020). 
 
It is worth noting that the unprecedented emergence of COVID-19 viruses has required the standard 
clinical trial procedure to be revised to cater to the dire needs of such vaccines. In responding to this 
demand, the government holds the responsibility to allow for expedited procedures of vaccine approval 
and still assure the safety and efficacy aspect of the vaccine. Instances of this rapid progress of clinical 
trials are evident in Australia, for example, in the COVID-19 candidate vaccine, V451 trial conducted 
by the University of Queensland (UQ), working hand in hand with the Commonwealth Serum 
Laboratories (CSL). Despite the recent launch of its extensive pre-clinical assessment in mid-February 
2020, the vaccine trial had then progressed to the first phase of the clinical trials after just five months 
in July 2020. Compared to the timeline of clinical trials in the pre-COVID-19 era, a significant 
reduction by at least seven months is seen here (Clinical Trials Arena, 2020). Fast forward to October 
2020, the candidate vaccine had successfully been tested upon one hundred twenty volunteers since the 
clinical trial inception (Australian Government, n.d.). Regrettably, by December 2020, V451 had to be 
abandoned as the human immunodeficiency virus (HIV) gp41 protein used in the candidate vaccine 
produced false-positive HIV antibody test results amongst Phase I participants (Blyth et al., 2021). 
  
Apart from the availability of data collection tools utilised during the previous pandemics, (Davis et al., 
2020) as can be seen in the UQ-CSL joint-venture COVID-19 vaccine trial, the clinical trials of 
COVID-19 vaccines managed to be expedited due to the combination of some of the trial stages so that 
they overlap between each other, and less time is required to complete the whole clinical trial process. 
For instance, results will be analysed without waiting for the studies on all participants in each stage to 
complete in Phase I and II. Instead, upon the availability of data gathered from the first few dozens of 
participants in Phase I, the research will immediately move on with hundreds more in Phase II. 
Similarly, clinical trials of Phase III in the COVID-19 era are instantly kicked off upon the availability 
of the preliminary data from Phase I and II (Department of Health, 2021b). Although the initial rollout 
of the COVID-19 vaccination is not part of the National Immunisation Program (NIP), the strength of 
the NIP in delivering a safe, efficient, effective, and transparent vaccination program must still be 
drawn while allowing a more flexible mechanism in ensuring its delivery promptly (Australian 
Government, n.d.).  
 
On the other hand, like Malaysia, unlike Australia, which does not develop vaccines, the monitoring of 
vaccine safety and efficacy should be viewed from a slightly different perspective. In complying with 
the WHO regulations, each set of vaccines used is required to be checked for compliance. The Ministry 
of Health (MOH) is responsible to monitor any side effect suffered by a person injected with a vaccine 
or known as Adverse Events Following Immunisation (AEFI). The Ministry of Health also adopts a 
strict requirement before accepting the vaccine for the National Immunisation program. The 
compliance of vaccine makers with Good Manufacturing Practice (GMP) regulations is one of the 
aspects considered. This is to ensure that the vaccines produced are of high quality and meet industry 
requirements while minimising any potential dangers throughout the production process. The NPRA's 
evaluation is based on international regulatory norms and procedures. WHO and the International 
Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use have 
established international regulatory standards (ICH). 
  
Currently, Malaysia is not involved in COVID-19 vaccine innovation and production. However, 
Malaysia is urging other vaccine-producing countries to collaborate in developing the COVID-19 
vaccine and is willing to provide its facilities, data, and resources to this effort. Once the vaccine is 





available, Malaysia is eager to participate in clinical trials. Because Malaysia is a multi-racial country, 
it is a good fit for human vaccine studies. Through science diplomacy efforts that were jointly carried 
out by the Ministry of Health (MOH), Ministry of Foreign Affairs (MFA), and the Ministry of Science, 
Technology, and Innovation (MOSTI) starting April 2020, the Government has adopted a multi-
pronged approach. This is to enable Malaysia to secure access to a portfolio of COVID-19 vaccines, 
which is being actively developed worldwide (The Secretariat of the Special Committee for Ensuring 
Access to Covid-19 Supply (JKJAV, 2021). 
  
The government action in addressing the safety issue of the COVID-19 vaccine can be evidenced in the 
cases of the AstraZeneca vaccine. In March 2021 there was widespread news in Malaysia claiming the 
fatal side effect of the AstraZeneca vaccine. The Malaysian Ministry of Health acted fast to investigate 
and reveal the outcome of the investigation (The Special Committee for Ensuring Access to COVID-19 
Vaccine, 2020). It was informed that the AstraZeneca vaccine which the Drug Control Authority has 
registered is safe to use in the country. The results of the evaluation of the data and the report found 
that the cases of blood clots were not directly related to the vaccine's side effects. AstraZeneca through 
a meeting with NPRA informed that as of 8 March 2020 a total of 17 million people has received the 
vaccine in countries around the European Union (EU). In United Kingdom (UK), out of the vaccine 
recipients involved, there were 15 cases of blood clots in the veins (Deep Vein Thrombosis syndrome 
or DVT), while another 22 cases involved blood clots in the pulmonary tract or Pulmonary Embolism. 
The company has made a detailed assessment of all these cases and concluded that there is no strong 
evidence to link the COVID-19 AstraZeneca vaccine with the risk of blood clots. The number of blood 
clotting cases reported is also much lower than the average number of cases expected to occur in that 
population size (World Health Organisation, 2021).  
 
 Registration of new vaccine 
  
In Australia, the Therapeutic Goods Act of 1989 serves as the foundation for market control, requiring 
that all medical products imported into, provided in, or exported from Australia be listed with the 
Australian Register of Therapeutic Goods (ARTG) before they may be supplied in or exported from 
Australia (Pharmaceuticals Export Promotion Council of India, 2018). Therapeutic goods, as defined 
by the Therapeutic Goods Act 1989, are goods that can be represented in any form and are used for 
therapeutic purposes. Generally, therapeutic goods are used to prevent, diagnose, cure or alleviate a 
disease, ailment, defect, or injury (Therapeutic Goods Administration, 2020). Under the Act, medicines 
and medical devices are the two primary categories of therapeutic goods. Vaccines are classified under 
the category of medicines. To be marketed for sale or distribution, all medicines including the Covid-
19 vaccine must be registered in the ARTG (Kumari et al., 2016).  
 
To allow a greater acceptance towards Covid-19 vaccination, vaccines as therapeutic goods are 
subjected to a high level of scrutiny and rigorous testing through the licensing and registration 
requirement under the Act. As such, the Therapeutic Goods Administration (TGA) is designated as the 
responsible regulatory authority through the said Act and the Therapeutic Goods Regulations 1990. 
TGA has been tasked to regulate COVID-19 vaccination through licensing of Australian manufacturers 
and verifying overseas manufacturers' compliance with the same standards as their Australian 
counterparts (Australian Covid-19 Vaccination Policy, 2020). Before the TGA could approve any 
license, a strict requirement will have to be adhered to and it is a practice that a vaccine will have to 
undergo several phases of rigorous clinical trials. Even before these clinical trials, there is a pre-clinical 
assessment stage whereby laboratory study is conducted before it being extended to animals in 
ensuring the safety and efficacy of the vaccine against the identified target antigen (National Centre for 
Immunisation Research and Surveillance, 2020). On the other hand, the Australian Technical Advisory 
Group on Immunisation (ATAGI) provides technical and clinical advice on vaccines' involvement in 
the National Immunisation Program and oversees the creation of the Australian Immunisation 
Handbook. In addition, the Australian Government formed the COVID-19 Vaccine Taskforce in 
response to the urgent need for action while the COVID-19 Vaccine and Treatments for Australia –
Science and Industry Technical Advisory Group (SITAG) is advising the government on potential 
vaccinations especially in the vaccine purchase decision. 
  





Provisional determination and registration application  
 
The utmost consideration in registering a vaccine lies in the fact that the benefits outweigh the risk 
exposed by vaccination (Association of State and Territorial Health Officials, 2020). The safety and 
timely availability of vaccines is largely attributed to the establishment of TGA in discharging their 
regulatory duties concerning the registration of vaccines. TGA plays a pivotal role in the initial 
regulatory approval for the use of COVID-19 vaccines through the provisional determination and 
registration pathway under the Therapeutic Goods Act of 1989. Section 22C until Section 22F of 
Therapeutic Goods Act 1989 obliges a pharmaceutical company to observe and comply with 
provisional determination application requirements. The Act specifies that sponsors must submit a 
detailed dossier containing information on clinical studies, non-clinical/toxicology investigations, 
chemistry, manufacturing, risk management, and other information to register a COVID-19 vaccine in 
Australia. TGA has to analyze the application based on the eligibility requirement and the product's 
safety, quality, efficacy, and the safety and quality of any new substances in the vaccine before 
approving it for registration. (Pharmout, 2016). This procedure also entails collecting additional 
information and clarification from the sponsor and consulting the Advisory Committee on Vaccines 
(ACV). The ACV was founded by The Australian Government Minister for Health with a special 
mandate to supplement TGA’s expertise and provide aid in registering a vaccine for use and 
distribution in Australia (Therapeutic Goods Administration (TGA), 2021). The members of the ACV 
are appointed by the Minister for Health under Regulation 39F of the Therapeutic Goods Regulations 
1990 and comprise professionals with distinct medical health experience as well as consumer 
representatives. To facilitate the process of approving a new vaccine, ACV is required to furnish 
independent medical advice to the TGA concerning any safety and quality issues. In the event a new 
vaccine is approved and registered in Australia, prescribers can be comfortable that the TGA has 
assessed its safety and efficacy with input from the ACV (Vaughan, 1995).  
 
The TGA will run checks on every batch of the vaccines and once it is satisfied with its safety, 
efficacy, and quality, approval will be granted for its use in Australia. The vaccines will then be 
provisionally registered in the Australian Register of Therapeutic Goods based on clinical evidence to 
achieve full registration as quickly as feasible (Department of Health Therapeutic Good 
Administration, 2021). The approval via the provisional approval pathway for COVID-19 vaccines is 
valid for an initial duration of two years entitling the pharmaceutical companies to legally supply the 
vaccines to Australian populations, subject to certain requirements, such as to supply continuous 
information to TGA on longer-term efficacy and safety based on ongoing clinical trials. This period 
could be further extended for up to two extensions amounting to a maximum of six years upon the 
application of the pharmaceutical companies (Therapeutic Goods Administration (TGA), 2021).  
 
Other than the primary legislation governing the registration of the Covid-19 vaccine, the Gene 
Technology Act 2001 regulates and controls the vaccine with genetically modified organisms (GMOs). 
Specifically, this Act primarily focused on the protection of health and safety of the people as well as 
the environment, by recognising and mitigating dangers posed by the gene technology, and by 
regulating specific dealings with GMOs (Australian Covid-19 Vaccination Policy, 2020). It is 
important to note that COVID-19 vaccines, such as adenovirus vaccines and some of the mRNA 
vaccines that use genetically modified organisms (GMOs) will have to undergo an extra layer of robust 
assessment by the Office of the Gene Technology Regulator (OGTR) for its approval and licensure 
(Australian Government, n.d.).  
 
In Malaysia, the National Pharmaceutical Regulatory Agency (NPRA) oversees reviewing and 
registering pharmaceutical (inclusive of vaccine) products. For drug-based products, the Control of 
Drugs and Cosmetics Regulation 1984 (Revised 2009) (CDCR, 1984) requires all drugs-based 
products to be registered (CDCR, 1984) before they can be manufactured, sold, supplied, imported, 
possessed, or administered in Malaysia. The law limits that only local distribution companies can 
submit a drug-based product registration application. Therefore, foreign companies with no local 
presence in Malaysia must use a Marketing Authorization Holder (MAH) as their local representative. 
MAH is responsible for the product application, as well as the quality, safety, and efficacy of the 
product (Regulation 7(1)(a), CDCR, 1984). 






In June 2014, NPRA in the Drug Evaluation Committee Meeting (no 9/2014) revised the Drug 
Registration Guidance Documents (DRGD) and inserted an amendment that requires the declaration of 
source of ingredients that derived from animal origin (active and excipient) including starting 
materials, gelatine, and the source of capsule shell on immediate container and outer carton labelling of 
all registered products through the Drug Registration Guidance Document (Drug Evaluation 
Committee Meeting No 17/2013). Besides the registration, licensing, and labelling requirements, the 
government also monitors and controls the drug product through batch-marking and product bans. 
Batch marking is done during the pre-marketing period and functions that also aid in monitoring post-
marketing activities. Through batch marking, defective drug products can be traced for recall or 
disbursement. Product bans on the other hand are a mechanism that involves immediate action of the 
authority to ban and prohibit the marketing and selling of a drug product that is defective and 
hazardous (Abdul Aziz, 2017). Premises handling, processing, and sale of drugs are inspected 
regularly. 
  
Conditional fast-track registration 
 
The 351st Meeting of the Drug Control Authority on 3 December 2020 agreed to the implementation 
of conditional fast-track registration for pharmaceutical products during disasters as provided under 
Regulation 8 of Control of Drug and Cosmetic Regulation (CDCR) 1984 and inserted as an annex 
under the Guideline on Conditional Registration for New Chemical Entities and Biologics in Malaysia 
Accordingly, a directive (Directive No. 18 of 2020) has been issued by the Director of Pharmaceutical 
Services on 15 December 2020 under the provisions of Regulation 29, CDCR 1984 to inform the 
holder registration in connection with the implementation of conditional fast-track registration for 
pharmaceutical products during a disaster. This conditional registration mechanism aims to provide 
immediate access to pharmaceutical products for current treatment or prevention of disaster by using a 
risk-based approach without ignoring aspects of product quality, safety, and effectiveness. 
  
The Dilemma of Anti-Vaccine Group 
  
During the COVID-19 crisis, pandemic doubters and those who reject wearing face masks or 
quarantine have already played a significant role in the pandemic's progression. Different anti-vaccine 
narratives are being constructed in response to the COVID-19 vaccine, and these narratives are likely 
to be adopted by huge populations, with serious repercussions. Similarly, both Australia and Malaysia 
face challenges imposed by the vaccine-hesitant group. Vaccine hesitancy has been highlighted as a 
major barrier to obtaining COVID-19 herd immunity, and some migrant groups are believed to be 
among the most vulnerable. Concerning this matter, both governments must understand the factors 
contributing to hesitancy towards COVID-19 vaccinations to support the initiation of a COVID-19 
vaccine program and ensure that communication efforts are targeted to factors impacting acceptability 
(Seale et al., 2021). In Australia, there was a drastic increase of groups spreading potentially harmful 
vaccine side effects and conspiracy theories (Wilson, 2021b). Between January 2020 and March 2021, 
the group's researchers employed CrowdTangle, a social media analysis tool, to track the evolution of 
13 public Facebook groups. These organisations ranged in size from major anti-vaccine organisations 
to minor organisations formed in response to Australia's COVID-19 public health policies. They 
discovered that throughout that time, the groups rose by 280 percent, to more than 115,000 members 
(Reset Australia Research Memo, 2021). The most active periods were during lockdowns and the 
licensing and implementation of the COVID-19 vaccines in Australia. 
  
The Australian government has previously implemented a policy known as "No Jab, No Pay" And “ 
No Jab, No Play” (Armiento et al., 2020). It means that if the adults do not get vaccinated, they would 
not be eligible for government assistance, and the children will be restricted from attending 
kindergartens or childcare centres. This was a response to the report that disclosed that vaccination was 
not given to over 40,000 Australian children under the age of seven because their parents rejected it 
(Gelling, 2021). As a result of the “No Jab, No Pay” regulation, many families will be unable to pay 
their bills (Gelling, 2021). During the spread of COVID-19, the anti-vaccine community has gotten 
more challenging to approach and has been underestimated. In March 2021, hundreds of people joined 





the “Millions March Against Mandatory Covid Vaccinations” events in Melbourne, Perth, Canberra, 
and Brisbane (Loomes, 2021). In Australia, nobody is required to have a mandatory vaccine including 
frontline workers and people who work in aged care. 
  
During the four weeks that the vaccine petition was open, over 300,000 individuals signed it. They 
claimed that the experimental vaccinations being tested for Covid-19 is going against the Nuremberg 
Code if made mandatory. This is a misinterpretation of research ethics, which prohibits the use of 
experimental treatments but not vaccines that have been demonstrated to be safe and effective (Wilson, 
2021a).  
  
In Malaysia, one of the thriving challenges to reach herd immunity comes from the anti-vaccine 
groups. Currently, it is not an offence under the Prevention and Control of Infectious Diseases Act 
1988 (Act 342) for individuals who refuse to receive COVID-19 vaccine injections in Malaysia. 
Vaccine injections through the National Immunisation Programme are made free and voluntarily on 
listed individuals. However, the Malaysian government is looking to take legal action against anti-
vaccine groups in the country if they are found to be inciting the public from supporting the National 
COVID-19 Immunisation Program (Berita Harian). The COVID-19 Vaccine Supply Assurance Special 
Committee is in the process to introduce the implementation of mandatory immunisation programs if 
the number of registrations fails to reach the group immunity target (Yeoh & Jua Wen, 2021). 
  
From the legal point of view, there are two discussions on the ability of the government to impose 
mandatory vaccination. First, looking at the way coronavirus has already reshaped our right to personal 
liberty, freedom of movement, and assembly that has made way to the right of the Government to 
impose requirements on its citizens to guarantee rights to life of the majority in the country. On the 
opposing view, it could be argued that enforcing vaccination amounted to oppression that is against the 
human rights principle. They argued that the physical nature of a vaccination that is piercing the skin 
sets it apart from restricting religious, civil, or political rights and even from forcing people to stay 
indoors or have their fingerprints taken. 
  
Access to vaccination 
 
The effort has been made by the government to ensure the continuous supply of vaccines to all 
populations in Australia. Limitation of vaccine supply in Australia and the urgency to reach herd 
immunity through vaccinations to avoid long-term transmission has led the way to the purchase of 
vaccines by the Australian Government(MacIntyre et al., 2021). Emphasising the purchasing and 
manufacturing of vaccines as one of the core measures under Australia’s COVID-19 Vaccine and 
Treatment Strategy, the government secured access to vaccines through direct procurement or 
manufacturing under license in Australia. The government has made significant gains in purchasing 
and manufacturing through:  
 
i. advance purchase agreements to assure the direct purchase of vaccination;  
ii. manufacturing agreements to increase the capability and capacity of Australian 
manufacturers; 
iii. international and multilateral agreements to encourage and ease of access for Australia; 
and 
iv. contracts for the purchase of products, resources, and services required for the distribution 
and administration of vaccines and treatments. 
(Australian Government, 2020) 
In the context of COVID-19 vaccines purchased for Australia, the government has entered into five 
separate agreements for the supply of COVID-19 vaccinations provided they are found to be safe and 
effective by the TGA (Department of Health, 2021b). For instance, Australia purchased the Novavax 
vaccine amounting to 40 million doses which will be delivered to Australia from foreign countries in 
the first half of 2021. Before a vaccine is accepted to be purchased by the government, all vaccines are 





required to pass different stages of research trials, rigorous assessment, and approval processes to 
prove the safety, quality, and efficacy of the vaccine. Concerning this matter, the approval obtained by 
Pfizer COVID-19 vaccines is subject to certain strict conditions, such as the need for Pfizer to continue 
providing data to the TGA on longer-term efficacy and safety from ongoing clinical trials and post-
market assessment (Department of Health Australian Government, 2021). It is also pertinent to note 
that unlawful imports of COVID-19 vaccine are regularly monitored as the TGA is working closely 
with Australian Border Force (ABF) and importers are subject to legal action in the event of any 
unapproved vaccines being imported to Australia (Therapeutic Goods Administration, 2021). 
Apart from the purchase of vaccines, the Australian government had manufactured the vaccines in the 
country. For instance, the Australian biopharmaceutical company, CSL plans to manufacture 30 
million doses of the University of Oxford vaccine or commonly known as AstraZeneca vaccine in 
Australia while another 3.8 million doses of AstraZeneca vaccine has been delivered to Australia from 
overseas in early 2021 manner (Australian Government, n.d.). On the other hand, international effort is 
apparent when the media reported that in September 2021, the governments of the United Kingdom 
and Australia will share COVID-19 vaccine doses to benefit each country's vaccination programme. 
The United Kingdom will send 4 million Pfizer/BioNTech vaccines to Australia to boost the Australian 
vaccination programme (Emily, 2021).  
 
On the issue of access to vaccination, the Malaysian government targeted 150,000 to 160,000 COVID-
19 vaccine deliveries by the middle of 2021 (Phase 3) when more supplies are received and more 
Vaccination Centers (PPVs) are opened. Procurement is carried out centrally at the MOH and direct 
deliveries are made to listed government facilities. Guaranteed access to the COVID-19 vaccine is 
through: 
i. Direct negotiation with the Product Registration Holder company/Vaccine 
Manufacturers/ Vaccine Distributors. 
ii. Direct negotiations through COVAX Facility. 
iii. Negotiations continue through bilateral agreements between the two countries (G2G). 
The first agreement was entered with COVAX Facility through an Optional Purchase Arrangement 
signed on 23 November 2020 that guarantees a supply of vaccines to 10 percent of the country's 
population, while the second agreement was an initial purchase agreement with pharmaceutical 
company Pfizer signed on 24 November the same year to secure a supply of vaccines for 20 percent of 
the country population (12.8 million doses) (Bernama, 2021b). The COVAX facility is a multi-pronged 
strategy approach that will enable countries to diversify their options as well as reduce the risk of 
focusing on only bilateral efforts to procure COVID-19 vaccines. The Government of Malaysia has 
also signed a cooperation agreement for the development and access to vaccines with the People's 
Republic of China on 18 November 2020 as an effort to secure access to vaccination for the people. 
This agreement constitutes a platform to give Malaysia priority in gaining access to COVID-19 
vaccines produced by the People's Republic of China. The international strategic cooperation whether 
multilateral or bilateral is Malaysia's step in supporting national aspirations and businesses' global 
solidarity towards combating COVID-19. It helps in diversifying vaccine procurement options for the 
country and reduces dependence on a single source only. 
  
The Malaysian Government has later signed the Terms Sheet document together with Pharmaniaga 
Lifescience Sdn Bhd and Solution Biologics Sdn Bhd to manufacture COVID-19 vaccine by fill and 
finish, which is the final filling process vaccine into vials before it is distributed. Through this step, the 
Sinovac vaccine and CanSinoBio are purchased in bulk and the manufacturing process is then 
implemented in Malaysia which in turn accelerates the adoption of vaccines. On top of that, the 
government negotiated with the Russian government for research and development (R&D) purposes, 
as well as production of Sputnik V vaccine in Malaysia to increase the total dose of COVID-19 












The study critically discusses the issues relating to vaccination activities that were based on past 
experiences and the current health crisis. Where many countries had experience battling pandemics that 
can spare some assistance in facing the current spread of COVID-19, but still due to some unique 
characteristics of the new attack, governments of the world need to devise their conventional way to 
eradicate the attack of the unseen virus. Discussion includes the adequacy of current law that 
sufficiently monitors the safety and efficacy of the newly created COVID-19 vaccine; the approved 
emergency expedited clinical trial for COVID-19 vaccine product, the scope of power of the Drug 
Control Authority, assuring access to vaccine and the risk posed by the vaccine-hesitant group. The 
findings can be summarised that governments of both countries unanimously have great concern over 
safety and efficacy issues relating to the newly invented vaccine. This concern is planted by the 
shortened period of clinical trial and the uncertain guarantee of immunology impact on the vaccinated 
people. Nevertheless, due to the desperate need, these countries have taken progressive actions to 
monitor and control any unprecedented outcome of the vaccination program. This study forwarded 
suggestions that may assist in addressing the issue of safety and efficacy of the COVID-19 vaccine 
product and the improvement on control and monitoring mechanisms that can be learned from both 
countries. Future research should delve into the issue of immunology of the COVID-19 vaccine in 
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